CLINICAL IMPORTANCE OF TRANSPORTER-MEDIATED DRUG-DRUG INTERACTIONS: BASICS AND APPLICATIONS OF EVIDENCE-BASED DECISION MAKING

被引：0
|
作者：
Maeda, Kazuya [1 ]
机构：
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Mol Pharmacokinet, Tokyo, Japan
来源：
DRUG METABOLISM REVIEWS | 2015年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
SC4.2
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [31] Predicting Transporter-mediated Drug Interactions
    Zhang, L.
    Sparreboom, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (04) : 447 - 449
  • [32] In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation
    Bi, Yi-an
    Kimoto, Emi
    Sevidal, Samantha
    Jones, Hannah M.
    Barton, Hugh A.
    Kempshall, Sarah
    Whalen, Kevin M.
    Zhang, Hui
    Ji, Chengjie
    Fenner, Katherine S.
    El-Kattan, Ayman F.
    Lai, Yurong
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (06) : 1085 - 1092
  • [33] Prediction of Clinical Transporter-Mediated Drug-Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models
    Carter, Simon J.
    Chouhan, Bhavik
    Sharma, Pradeep
    Chappell, Michael J.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (04): : 211 - 221
  • [34] Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey
    Kosa, Rachel E.
    Lazzaro, Sarah
    Bi, Yi-an
    Tierney, Brendan
    Gates, Dana
    Modi, Sweta
    Costales, Chester
    Rodrigues, A. David
    Tremaine, Larry M.
    Varma, Manthena V.
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (08) : 1179 - 1189
  • [35] Response to the Comment on the Article "Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions"
    Varma, Manthena V. S.
    Lai, Yurong
    Feng, Bo
    Litchfield, John
    Goosen, Theunis C.
    Bergman, Arthur
    PHARMACEUTICAL RESEARCH, 2013, 30 (06) : 1469 - 1470
  • [36] TRANSPORTER-MEDIATED DRUG-DRUG INTERACTIONS: EVALUATION USING RNAI TECHNOLOGY WITH PRIMARY HUMAN CELLS
    Webber, Guy
    Pal, Akos
    Wood, Stuart
    DRUG METABOLISM REVIEWS, 2012, 44 : 151 - 151
  • [37] Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”
    Manthena V. S. Varma
    Yurong Lai
    Bo Feng
    John Litchfield
    Theunis C. Goosen
    Arthur Bergman
    Pharmaceutical Research, 2013, 30 : 1469 - 1470
  • [38] Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast
    Varma, M. V.
    Kimoto, E.
    Scialis, R.
    Bi, Y.
    Lin, J.
    Eng, H.
    Kalgutkar, A. S.
    El-Kattan, A. F.
    Rodrigues, A. D.
    Tremaine, L. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (03) : 406 - 415
  • [39] Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions
    Maeda, Kazuya
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : 76 - 88
  • [40] Using Endogenous Biomarkers to Derisk Assessment of Transporter-Mediated Drug-Drug Interactions: A Scientific Perspective
    Arya, Vikram
    Reynolds, Kellie S.
    Yang, Xinning
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (12): : 1501 - 1506
12345